Rein Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Rein Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $0 | Apr 2, 2018 |
| FY2017 | Dec 31, 2015 | $0 | Apr 2, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Mar 29, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($49.87M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($62.88M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($15.73M) | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | ($27.33M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($26.16M) | Mar 20, 2023 |
| FY2020 | Dec 31, 2020 | ($4.93M) | Mar 24, 2021 |
| FY2020 | Sep 30, 2020 | ($5.02M) | Mar 24, 2021 |
| FY2020 | Jun 30, 2020 | ($4.39M) | Mar 24, 2021 |
| FY2020 | Mar 31, 2020 | ($6.81M) | Mar 24, 2021 |
| FY2020 | Dec 31, 2019 | ($7.24M) | Mar 24, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($50.63M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($65.11M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($16.28M) | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | ($27.65M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($26.61M) | Mar 20, 2023 |
| FY2020 | Dec 31, 2020 | ($4.19M) | Mar 24, 2021 |
| FY2020 | Sep 30, 2020 | ($5.03M) | Mar 24, 2021 |
| FY2020 | Jun 30, 2020 | ($4.40M) | Mar 24, 2021 |
| FY2020 | Mar 31, 2020 | ($6.88M) | Mar 24, 2021 |
| FY2020 | Dec 31, 2019 | ($7.35M) | Mar 24, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.03M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $14.25M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $3.99M | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | $17.97M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $17.01M | Mar 20, 2023 |
| FY2020 | Dec 31, 2020 | $1.93M | Mar 24, 2021 |
| FY2020 | Sep 30, 2020 | $2.68M | Mar 24, 2021 |
| FY2020 | Jun 30, 2020 | $2.49M | Mar 24, 2021 |
| FY2020 | Mar 31, 2020 | $4.07M | Mar 24, 2021 |
| FY2020 | Dec 31, 2019 | $4.71M | Mar 24, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($19.36M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($22.29M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($19.81M) | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | ($24.87M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($23.75M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($20.48M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($26.47M) | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | ($27.93M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($20.53M) | Mar 29, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $157.0K | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $5.0K | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $151.0K | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $4.42M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $142.0K | Mar 29, 2019 |
| FY2017 | Dec 31, 2015 | $94.0K | Apr 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.16M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $62.19M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $106.01M | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | $22.01M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $48.48M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $16.34M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $26.47M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $30.31M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $52.69M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $22.02M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.24M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $7.80M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $7.71M | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | $3.38M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $4.58M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $4.18M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $10.43M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $10.71M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $4.89M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $4.08M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.92M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $54.39M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $98.30M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $18.62M | Apr 7, 2025 |
| FY2022 | Dec 31, 2021 | $43.90M | Mar 20, 2023 |
| FY2022 | Dec 31, 2020 | $12.16M | Mar 20, 2023 |
| FY2021 | Dec 31, 2019 | $16.05M | Mar 28, 2022 |
| FY2020 | Dec 31, 2018 | $19.60M | Mar 24, 2021 |
| FY2019 | Dec 31, 2017 | $47.80M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | ($111.81M) | Mar 29, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.33M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $6.33M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $6.33M | Apr 7, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($401.27M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($351.40M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($288.52M) | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | ($272.79M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($245.46M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($219.29M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($198.14M) | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | ($168.49M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($136.95M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($114.34M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.22M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $12.87M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $17.34M | Mar 26, 2026 |
| FY2023 | Dec 31, 2022 | $5.19M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $3.60M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $7.05M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $5.31M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $10.64M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $11.86M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $20.72M | Apr 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | (6) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | (5) | Mar 20, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | (6) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | (5) | Mar 20, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 27.55M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 21.67M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 4.89M | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | 4.54M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | 4.53M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | 43.80M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 27.81M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | 14.75M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 14.72M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | 432,413 | Apr 2, 2018 |